Integra LifeSciences cut to Hold at Argus amid inconsistent performance

As previously reported, Argus analyst David Toung downgraded Integra LifeSciences (IART) to Hold from Buy. The company’s operating performance has been inconsistent as it has faced multiple quality control issues in its manufacturing facilities, the analyst tells investors in a research note. The firm adds, however, that there is still underlying demand for Integra’s regenerative tissue products and specialty surgery products, noting that if the firm sees better sales execution to fulfill that demand, it would consider returning the stock to a Buy rating.